Published in Z Gastroenterol on March 01, 1984
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery (1991) 1.62
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest (1991) 1.41
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Soluble Tac peptide is present in the urine of normal individuals and at elevated levels in patients with adult T cell leukaemia (ATL). Clin Exp Immunol (1988) 1.20
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther (1984) 1.11
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res (1990) 1.04
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol (1989) 0.99
Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol (1989) 0.98
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Use of serum amyloid A and other acute phase reactants to monitor the inflammatory response after castration in horses: a field study. Equine Vet J (2005) 0.94
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
The cytoprotective effects of (+/-)-15-deoxy-16-alpha, beta-hydroxy-16-methyl PGE1 methyl ester (sc-29333) versus aspirin-shock gastric ulcerogenesis in the dog. Prostaglandins (1981) 0.94
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol (1997) 0.92
Toxicological studies on malachite green: a triphenylmethane dye. Arch Toxicol (1984) 0.91
Effect of supplemental dietary glutamine on methotrexate concentrations in tumors. Arch Surg (1992) 0.91
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1980) 0.90
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. Infect Immun (1991) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor. Cancer Res (1990) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Disposition of valproic acid in man. Eur J Clin Pharmacol (1977) 0.85
Biomonitoring of genotoxic exposure among stainless steel welders. Mutat Res (1992) 0.85
Studies of mutagenicity and clastogenicity of 5-azacytidine in human lymphoblasts and Salmonella typhimurium. Mutat Res (1986) 0.84
Analytical and numerical modelling of Newtonian and non-Newtonian liquid in a rotational cross-flow MBR. Water Sci Technol (2012) 0.84
Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmacol Ther (1987) 0.84
[Purification and characterization of a 3'-phosphoadenylylsulfate: steroid sulfotransferase from human liver]. Biochim Biophys Acta (1970) 0.83
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clin Pharmacol Ther (1982) 0.83
Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther (1987) 0.83
[Drugs interacting with coumarine oral anticoagulants (author's transl)]. Klin Wochenschr (1973) 0.82
Spontaneous and induced chromosomal aberrations and gene mutations in human lymphoblasts: mitomycin C, methylnitrosourea, and ethylnitrosourea. Mutat Res (1986) 0.82
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat (2004) 0.82
Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J Chromatogr (1983) 0.82
Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J (1984) 0.82
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Ultrasound-guided emergency endoscopic retrograde biliary drainage without radiography. Endoscopy (1997) 0.81
Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr (1985) 0.80
Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klin Wochenschr (1985) 0.79
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Cancer Epidemiol Biomarkers Prev (1999) 0.79
Determination of disulfiram and metabolites from biological fluids by high-performance liquid chromatography. J Chromatogr (1980) 0.79
[Incidence of catechol-O-methyltransferase in human erythrocytes]. Arch Int Pharmacodyn Ther (1973) 0.79
[Frequency of surgery in ulcer after the introduction of H2-blockers]. Dtsch Med Wochenschr (1984) 0.78
[Treatment failure of cimetidine in duodenal ulcer (author's transl)]. Dtsch Med Wochenschr (1982) 0.78
[Hepatic drug interactions]. Fortschr Med (1985) 0.78
Influence of phenobarbital treatment on cimetidine kinetics. Eur J Clin Pharmacol (1981) 0.78
[Purification and characterization of human placenta S-adenosylmethionine:catechol-O-methyltransferase]. Biochim Biophys Acta (1970) 0.78
[Granulomatous colitis with pseudopolyp in schistosomiasis]. Dtsch Med Wochenschr (1989) 0.78
Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology (1999) 0.77
Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther (1983) 0.77
The pharmacokinetic properties of beta adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.77
Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr (1985) 0.77
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol (1992) 0.76
Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet (1979) 0.76
Cimetidine excretion into breast milk. Br J Clin Pharmacol (1979) 0.76
Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther (1985) 0.76
Cimetidine disposition in obesity. Am J Gastroenterol (1984) 0.76
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol (1981) 0.75
Altered disposition and availability of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol (1982) 0.75
[The course of Crohn disease and side effect profile with long-term treatment using metronidazole]. Z Gastroenterol (1989) 0.75